GLP-1 receptor activation helps reduce appetite by signalling to the brain that you are satisfied, slows gastric emptying to keep you feeling fuller for longer, and improves insulin secretion when blood glucose levels rise
AASLD guidance recommends considering them in patients with concurrent co-morbidities such as obesity and diabetes given their potential benefit in NAFLD
Pre-diabetes and metabolic syndrome are growing health concerns that affect millions of people
Starting low, progressing gradually, and adjusting thoughtfully creates the best foundation for long-term success and a better overall experience
GLP-2 is a 33-amino acid peptide hormone that, like GLP-1, is secreted from intestinal L-cells in response to nutrient intake
Comparative work with semaglutide (GLP-1R only) and tirzepatide (GIPR + GLP-1R) provides the field with a comprehensive map of how incremental receptor engagement reshapes downstream pharmacology across pancreatic, hepatic, adipose, and central nervous system tissues